GTL001, a Therapeutic Vaccine for Women Infected With Human Papillomavirus 16 or 18 and Normal Cervical Cytology: Results of a Phase I Clinical Trial

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-0085
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

GTL001, a Bivalent Therapeutic Vaccine Against Human Papillomavirus 16 and 18, Induces Antigen-Specific CD8+ T Cell Responses Leading to Tumor Regression

PLoS ONE
Multidisciplinary
2017English

Human Papillomavirus Type 16 and 18 Viral Loads as Predictors Associated With Abnormal Cervical Cytology Among Women in Saudi Arabia

Heliyon
Multidisciplinary
2020English

A Novel Vaccine for Cervical Cancer: Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine (Gardasil®)

Therapeutics and Clinical Risk Management
2008English

Trends in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers, 2008–2014

Cancer Epidemiology Biomarkers and Prevention
MedicineEpidemiologyOncology
2019English

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine

Drugs
Pharmacology
2011English

A Study of Genotyping for Management of Human Papillomavirus-Positive, Cytology-Negative Cervical Screening Results

Journal of Clinical Microbiology
Microbiology
2014English

Cytomegalovirus Vaccine: Phase II Clinical Trial Results

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2014English

Estimating the Long-Term Impact of a Prophylactic Human Papillomavirus 16/18 Vaccine on the Burden of Cervical Cancer in the UK

British Journal of Cancer
Cancer ResearchOncology
2006English

Gene Therapy for Pain: Results of a Phase I Clinical Trial

Annals of Neurology
Neurology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy